Clinical Trial Update: A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period [Phase 2, Phase 3]

View source ↗

Summary

12-week study of Pramipexole Extended Release in Parkinson disease followed by a 52-week long-term treatment period; the Phase 2/3 trial completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Pramipexole ER (pramipexole)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Parkinson Disease | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2011-02-10